Takis second Biotech in Europe at EIT Health Catapult Final!
Takis second Biotech in Europe at EIT Health Catapult Final
Paris, 2 December, 2019 – NeoMatrix, a neoantigen-based cancer vaccine based on Precision Immunology has been awarded second among the best Biotech companies in Europe. The journey started this summer, when a though selection of 150 companies led to a list of 7 finalists.
“The EIT Health Catapult competition was a great experience and most importantly validated NeoMatrix concept and business model” said Dr. Fabio Palombo, Director of NeoMatrix. “We have all the tools to make our dream real: provide new cures to cancer patients.”
“This is an fantastic recognition of our work and our ideas” said Luigi Aurisicchio, CEO/CSO. “We are more and more motivated to move forward NeoMatrix to clinical trial. In Paris we had the opportunity to meet many other stakeholders, learn each other and above all to establish a great network for future collaborations. ”
Are you ready to be "catapulted" in the Future of Cancer Therapy?